The aim of this study is to evaluate the feasibility and safety of delegating remote biological monitoring in post-hospitalization for cardiac decompensation by a heart failure nurse.
Chronic heart failure is a major public health issue in France. It is the leading cause of hospitalisation in people over 65 years of age and results in many costly and potentially avoidable hospital stays. One third of patients are readmitted to hospital within 3 months of discharge. A remote monitoring programme and natriuretic peptide monitoring during this vulnerable period can help improve patient management, reducing rehospitalisation rates, emergency room visits and mortality. Given the increasing pressure on already limited healthcare resources, it is important to examine the delegation of care to specialist nurses, as well as their safety. This study aims to evaluate the feasibility and safety of delegating remote biological monitoring in post-hospitalization for cardiac decompensation by a heart failure nurse.
Study Type
OBSERVATIONAL
Enrollment
100
Review of biological results by a nurse (IDE) trained in heart failure monitoring, alongside the cardiologist, at S1, S2, M1, M2 and M3.
Cardiology department - Hospital NOVO - Pontoise site
Pontoise, France
Assessment of the concordance, appropriateness and safety of nursing decisions in post-hospitalization heart failure
The relevance and safety of IDE decisions will be determined by the concordance rate between the decisions made by the cardiologist and the IDE following the biological results at each check-up and after blind review by a second cardiologist
Time frame: At the end of the patient's follow-up, an average of 3 month
Assessment of the risk of rehospitalisation in the study population between discharge and M3
The risk of rehospitalization and death will be assessed, to see if a significant difference is observed between IDE decisions and cardiologist decisions, with items listed below : * Number of interventions initiated, * Number of rehospitalisation for all causes and for heart failure. * Number of emergency room visits for heart failure and all causes.
Time frame: At the end of the patient's follow-up, an average of 3 month
Assessment of the risk of death in the study population between discharge and M3
The risk of death will be assessed by the rate of death for all-cause and cardiac to see if a significant difference is observed between IDE decisions and cardiologist decisions.
Time frame: At the end of the patient's follow-up, an average of 3 month
Impact of the organisation on patient outcomes at M3 (Brain natriuretic peptide)
The impact of the organisation, favourable or unfavourable, on patient outcomes will be assessed by the evolution of the following item : \- Brain natriuretic peptide levels between discharge and three months,
Time frame: At the end of the patient's follow-up, an average of 3 month
Impact of the organisation on patient outcomes at M3 (New York Heart Association (NYHA))
The impact of the organisation, favourable or unfavourable, on patient outcomes will be assessed by the evolution of the following item : \- New York Heart Association (NYHA) score from discharge to three months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At the end of the patient's follow-up, an average of 3 month
Assessment of the feasibility of the patient monitoring system
The feasibility of the patient monitoring system will be assessed in relation to the number of biological tests not performed. If the number of biological tests not performed is too high, the patient monitoring system will not be validated.
Time frame: At the end of the patient's follow-up, an average of 3 month